**AVELUMAB**

**TRADE NAME** BAVENCIO

**DRUG CLASS** Non-cytotoxic antineoplastic, monoclonal antibody

**AVAILABILITY** Vial contains 200 mg/10 mL of avelumab. Also contains mannitol, glacial acetic acid, polysorbate 20 and sodium hydroxide.\(^1\)

The solution is clear and colourless to slightly yellow.\(^1\)

**WARNING**

Anaphylactic reactions may occur. Resuscitation facilities must be readily available.\(^1\)

The occupational hazard of intermittent low dose exposure to avelumab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure. Avelumab is not cytotoxic.


**pH** 5.0–5.6\(^1\)

**PREPARATION** Dilute before use.

**STABILITY** Vial: store at 2 to 8 °C. Do not freeze. Protect from light.\(^1\)

Infusion solution: stable for up to 8 hours below 25 °C.\(^1\) Store for up to 24 hours at 2 to 8 °C. Do not freeze. Do not shake. If refrigerated allow to reach room temperature before use.\(^1\)

**ADMINISTRATION**

**IM injection** Not recommended

**SUBCUT injection** Not recommended

**IV injection** Not recommended\(^1\)

**IV infusion** Dilute the dose in 250 mL of a compatible fluid. Gently invert the bag to mix. Do not shake. Infuse over 1 hour using a low protein binding 0.2 micrometre filter inline or add on filter.\(^1\)

**COMPATIBILITY**

**Fluids** sodium chloride 0.45%; sodium chloride 0.9%\(^1\)

**Y-site** No information

**INCOMPATIBILITY** No information

**SPECIAL NOTES** Give an antihistamine and paracetamol before the first four infusions.\(^1\)

Infusion reactions are common and include pyrexia, chills, flushing, hypotension, dyspnoea, wheezing, back and abdominal pain and urticaria. If a Grade 1 infusion reactions occurs, slow the rate of the infusion by 50%. For a Grade 2 reaction stop the infusion until it is Grade 1 or resolved and then restart at the 50% slower rate. For Grade 3 or 4 reactions, stop the infusion.\(^1\)